We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J.B. HuntTransportation Services, Inc. (JBHT - Free Report) reported first-quarter 2018 earnings per share of $1.07, missing the Zacks Consensus Estimate of $1.09.
How Was the Estimate Revision Trend?
Investors should note that the earnings estimate revisions for J.B. Hunt depicted a healthy picture prior to the earnings release. The stock had seen the Zacks Consensus Estimate for first-quarter earnings being revised 1.9% upward over the last 90 days.
However, J.B. Hunt has an unimpressive earnings surprise history. The company has surpassed the Zacks Consensus Estimate in only two of the last four quarters with an average miss of 0.7%.
J.B. Hunt Transport Services, Inc. Price and EPS Surprise
J.B. Hunt recorded revenues of $1,948.2 million, which surpassed the Zacks Consensus Estimate of $1,872.1 million.
Key Q1 Statistics: During the quarter, the company did not repurchase shares. As on Mar 31, 2018, the company had around $521 million shares remaining under its share buyback program. Operating income in the first quarter increased 12.9% to $168.8 million (on a reported basis). Outstanding debt was $1 billion at the end of the quarter.
Check back later for our full write up on this J.B. Hunt earnings report later!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
J.B. Hunt (JBHT) Misses on Q1 Earnings
J.B. Hunt Transportation Services, Inc. (JBHT - Free Report) reported first-quarter 2018 earnings per share of $1.07, missing the Zacks Consensus Estimate of $1.09.
How Was the Estimate Revision Trend?
Investors should note that the earnings estimate revisions for J.B. Hunt depicted a healthy picture prior to the earnings release. The stock had seen the Zacks Consensus Estimate for first-quarter earnings being revised 1.9% upward over the last 90 days.
However, J.B. Hunt has an unimpressive earnings surprise history. The company has surpassed the Zacks Consensus Estimate in only two of the last four quarters with an average miss of 0.7%.
J.B. Hunt Transport Services, Inc. Price and EPS Surprise
J.B. Hunt Transport Services, Inc. Price and EPS Surprise | J.B. Hunt Transport Services, Inc. Quote
Revenues Higher Than Expected
J.B. Hunt recorded revenues of $1,948.2 million, which surpassed the Zacks Consensus Estimate of $1,872.1 million.
Key Q1 Statistics: During the quarter, the company did not repurchase shares. As on Mar 31, 2018, the company had around $521 million shares remaining under its share buyback program. Operating income in the first quarter increased 12.9% to $168.8 million (on a reported basis). Outstanding debt was $1 billion at the end of the quarter.
Zacks Rank: Currently, J.B. Hunt carries a Zacks Rank #3 (Hold) which is subject to change following the earnings announcement. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on this J.B. Hunt earnings report later!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>